Skip to main content
SpringerLink
Log in

Benefits and Risks of Torasemide in Congestive Heart Failure and Essential Hypertension

  • Review Articles
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Torasemide is a lipophilic anilinopyridine sulphonylurea derivative that acts as a high ceiling loop diuretic and has been used for the treatment of both acute and chronic congestive heart failure (CHF) and hypertension. Torasemide is similar to other loop diuretics in terms of its mechanism of diuretic action; namely, blockade of Na+/K+/2Cl− cotransport in the thick ascending limb of the loop of Henle. It has high bioavailability (>80%), as does bumetanide, but a longer elimination half-life (3 to 4 hours) than either bumetanide or furosemide (frusemide).

In the treatment of chronic CHF, oral torasemide (5 to 20 mg/day) has been shown to be an effective diuretic. Patients treated with torasemide for up to 1 year have reduced bodyweight, improved pulmonary haemodynamics, and decreased CHF severity. Intravenous torasemide (20 to 60mg as a single dose) has been shown to be as effective as furosemide in the treatment of acute CHF, and resulted in significant diuresis, bodyweight loss, and improved pulmonary haemodynamics and exercise performance.

‘Non-diuretic’ dosages (2.5 to 5 mg/day) of oral torasemide have been used to treat essential hypertension, both as monotherapy and in combination with other antihypertensive agents. When used in these dosages, torasemide lowered diastolic blood pressure (DBP) to below 90mm Hg in 8 to 12 weeks in 70 to 80% of patients. With dose doubling, this level of efficacy occurred in more than 90% of hypertensive patients. Clinical trials have established that blood pressure can be maintained at this level for at least 1 year with low dose torasemide.

Torasemide is well tolerated in dosages up to 20 mg/day for at least 1 year. The most commonly reported adverse effects are those associated with loop diuretics in general. These include transient hypokalaemia, hyperuricaemia, dizziness, headache, gastrointestinal disturbances, orthostatic hypotension and fatigue. Adverse effects are comparable with those of other diuretics and rarely necessitate drug withdrawal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Friedel HA, Buckley MM. Torasemide: a review of its pharmacological properties and therapeutic potential. Drugs 1991; 41: 81–103.

    Article  PubMed  CAS  Google Scholar 

  2. Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121–42.

    Article  PubMed  CAS  Google Scholar 

  3. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92.

    Article  PubMed  CAS  Google Scholar 

  4. Lohrmann R, Burhoff I, Greger R. Tubular effects of the diuretic torasemide. Cardiology 1994; 84 Suppl. 2: 135–42.

    Article  PubMed  CAS  Google Scholar 

  5. Giebisch G, Klein-Robbenhaar G, Klein-Robbenhaar J, et al. Renal and extrarenal sites of action of diuretics. Cardiovasc Drugs Ther 1993; 7: 11–21.

    Article  PubMed  Google Scholar 

  6. Puschett JB, Jordan LL. Mode of action of torasemide in man. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 3–13.

    Google Scholar 

  7. Barr WH, Smith HL, Karnes HT, et al. Torasemide dose-proportionality of pharmacokinetics and pharmacodynamics. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 29–37.

    Google Scholar 

  8. Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991; 41 Suppl. 3: 14–22.

    Article  PubMed  Google Scholar 

  9. Scheen AJ. Dose-response curve for torasemide in healthy volunteers. Arzneimittel Forschung 1988; 38: 156–9.

    PubMed  CAS  Google Scholar 

  10. von Möllendorff E, Neugebaur G. Pharmacokinetics of torsemide in patients with congestive heart failure. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 73–80.

    Google Scholar 

  11. Kramer WG. Pharmacokinetics and pharmacodynamics of torsemide in congestive heart failure. Cardiology 1994; 84 Suppl. 2: 108–14.

    Article  PubMed  Google Scholar 

  12. Delarge J. Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide. Arzneimittel Forschung 1988; 38: 144–50.

    PubMed  CAS  Google Scholar 

  13. Neugebauer G, Besenfelder E, von Möllendorff E. Pharmacokinetics and metabolism of torasemide in man. Arzneimittel Forschung 1988; 38: 164–6.

    PubMed  CAS  Google Scholar 

  14. Miners JO, Rees DLP, Valente L, et al. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torasemide metabolism. J Pharmacol Exp Ther 1995; 272: 1076–81.

    PubMed  CAS  Google Scholar 

  15. Barr WH, Smith H, Karnes HT, et al. Comparison of bioavailability, pharmacokinetics and pharmacodynamics of torasemide in young and elderly healthy volunteers. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 15–28.

    Google Scholar 

  16. Andreasen F, Hansen U, Husted SE, et al. The pharmacokinetics of furosemide are affected by age. Br J Clin Pharmacol 1983; 16: 391–7.

    Article  PubMed  CAS  Google Scholar 

  17. Kerremans LM, Tan Y, van Baars H, et al. Furosemide kinetics and dynamics in aged patients. Clin Pharmacol Ther 1983; 34: 181–9.

    Article  PubMed  CAS  Google Scholar 

  18. Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370–7.

    PubMed  CAS  Google Scholar 

  19. Silke B. Central hemodynamic effects of diuretic therapy in chronic heart failure. Cardiovasc Drugs Ther 1993; 7: 45–53.

    Article  PubMed  Google Scholar 

  20. Silke B. Haemodynamic impact of diuretic therapy in chronic heart failure. Cardiology 1994; 84 Suppl. 2: 115–23.

    Article  PubMed  Google Scholar 

  21. Taylor SH. Diuretics in heart failure: some knowns and unknowns. J Cardiovasc Pharmacol 1993; 22 Suppl. 3: S40–S50.

    Article  PubMed  Google Scholar 

  22. Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J 1994; 72 Suppl.: S40–S43.

    Article  PubMed  CAS  Google Scholar 

  23. Brater DC. Pharmacokinetics and pharmacodynamics of torasemide in health and disease. J Cardiovasc Pharm 1994; 22 Suppl. 3:S24–S31.

    Article  Google Scholar 

  24. Brater DC, Day B, Burdette A, et al. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26: 183–9.

    Article  PubMed  CAS  Google Scholar 

  25. Vasko MR, Brown-Cartwright D, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985; 102: 314–8.

    PubMed  CAS  Google Scholar 

  26. Vargo D, Kramer WG, Black PK, et al. The pharmacodynamics of torsemide in patients with congestive heart failure. Clin Pharmacol Ther 1994; 56: 48–54.

    Article  PubMed  CAS  Google Scholar 

  27. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57: 601–9.

    Article  PubMed  CAS  Google Scholar 

  28. Cody RJ, Spencer HK, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994; 154: 1905–4.

    Article  PubMed  CAS  Google Scholar 

  29. Brater DC. Resistance to loop diuretics: why it happens and what to do about it. Drugs 1985; 49: 241–7.

    Google Scholar 

  30. Stroobandt R, Dodion L, Kesteloot H. Clinical efficacy of torasemide, a new diuretic, in patients with acute heart failure: a double blind comparison with furosemide. Arch Int Pharmacodyn 1982; 260: 151–8.

    PubMed  CAS  Google Scholar 

  31. Stringer KA, Watson W, Gratton M, et al. Intravenous torsemide as adjunctive therapy in patients with acute pulmonary edema. J Clin Pharmacol 1994; 34: 1083–7.

    PubMed  CAS  Google Scholar 

  32. Bremner S, Hariman RJI, Kostis JB, et al. Comparison of intravenous torsemide and furosemide in moderate to severe congestive heart failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 49–50.

    Google Scholar 

  33. Hariman RJ, Bremner S, Louie EK, et al. Dose-response study of intravenous torsemide in congestive heart failure. Am Heart J 1994; 128: 352–7.

    Article  PubMed  CAS  Google Scholar 

  34. Scheen AJ, Vancrombreucq JC, Delarge J, et al. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 1986; 31 Suppl.: 35–42.

    Article  PubMed  Google Scholar 

  35. Langbehn A, Achhammer I, Bölke T. Acute hemodynamic effects of 20 mg torasemide and 20 mg furosemide given intravenously to patients with congestive heart failure. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 147–55.

    Google Scholar 

  36. Isbary J, Achhammer I, Wetzeis E. The influence of 20 mg torasemide i.v. and 20 mg furosemide i.v. on hemodynamics and diuresis in patients with high grade left heart failure. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 137–46.

    Google Scholar 

  37. Fiehring H, Achhammer I. Influence of 10 mg torasemide i.v. and 20 mg furosemide i.v. on the intracardiac pressures in patients with heart failure at rest and during exercise. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 97–104.

    Google Scholar 

  38. Patterson JH, Adams KF, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy 1994; 14: 514–21.

    PubMed  CAS  Google Scholar 

  39. Mattioli AV, Castellani ET, Casali E. Symptomatic achievements with diuretics in congestive heart failure. Cardiology 1994; 8 Suppl. 2: 131–4.

    Article  Google Scholar 

  40. Stauch M, Stiehl L. Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide and furosemide in patients with congestive heart failure: a multicenter study. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 121–6.

    Google Scholar 

  41. Piesche L, Achhammer I, Glocke M, et al. Comparison of torasemide with furosemide in patients with chronic heart failure. In: Puschett JB, Greenberg A, editors. Diuretics II: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1987: 65–7.

    Google Scholar 

  42. Goebel K-M. Six-week study of torsemide in patients with congestive heart failure. Clin Ther 1993; 15: 1051–9.

    PubMed  CAS  Google Scholar 

  43. Achhammer I, Häcker W, Glocke M. Efficacy and safety of torasemide in patients with chronic heart failure. Arzneimittel Forschung 1988; 38: 184–7.

    PubMed  CAS  Google Scholar 

  44. Achhammer I. Long term efficacy and tolerance of torasemide in congestive heart failure. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 126–36.

    Google Scholar 

  45. Düsing R, Piesche L. Second line therapy of congestive heart failure with torasemide. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 105–20.

    Google Scholar 

  46. Podszus T, Piesche L. Effect of torasemide on pulmonary and cardiac hemodynamics after oral treatment of chronic heart failure. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 157–66.

    Google Scholar 

  47. Podszus T, Wagner U, Ploch T. Clinical and haemodynamic effects of long-term treatment with torasemide in congestive heart failure. Cardiology 1994; 84 Suppl. 2: 124–30.

    Article  PubMed  Google Scholar 

  48. Lehnert H, Schmitz H, Beyer J, et al. Controlled clinical trial investigating the influence of torasemide and furosemide on carbohydrate metabolism in patients with cardiac failure and concomitant type II diabetes. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 271–4.

    Google Scholar 

  49. Weinberger MH. Diuretics and their side effects: dilemma in the treatment of hypertension. Hypertension 1988; 11 Suppl. II: 16–20.

    Google Scholar 

  50. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 Suppl. 3: 32–9.

    Article  Google Scholar 

  51. Schmieder RE, Rockstroh JK. Efficacy and tolerance of low-dose loop diuretics in hypertension. Cardiology 1994; 84 Suppl. 2: 36–42.

    Article  PubMed  Google Scholar 

  52. Reyes AJ. Renal excretory profiles of loop diuretics: consequences for therapeutic application. J Cardiovasc Pharmacol 1993; 22 Suppl. 3: S11–S23.

    Article  PubMed  CAS  Google Scholar 

  53. Uchida T, Yamanaga K, Kido H, et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 Suppl. 2: 14–7.

    Article  PubMed  CAS  Google Scholar 

  54. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145–50.

    Article  PubMed  CAS  Google Scholar 

  55. Uchida T, Kido H, Yamanaga K, et al. A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery. Prostaglandins Leukot Essent Fatty Acids 1992; 45: 121–4.

    Article  PubMed  CAS  Google Scholar 

  56. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension: experience with torasemide. Drugs 1991; 41 Suppl. 3: 80–91.

    Article  PubMed  Google Scholar 

  57. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7: 63–8.

    Article  PubMed  Google Scholar 

  58. Dupont AG, Schoors D, Six RO, et al. Antihypertensive efficacy of low dose torasemide in essential hypertension. J Human Hypertens 1988; 2: 265–8.

    CAS  Google Scholar 

  59. Baumgart P, Walger P, van Eiff M, et al. Long-term efficacy and tolerance of torasemide in essential hypertension. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 169–82.

    Google Scholar 

  60. Spannbrucker N, Achhammer I, Metz P, et al. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittel Forschung 1988; 38: 190–3.

    PubMed  CAS  Google Scholar 

  61. Reyes AJ, Chiesa PD, Santucci MR, et al. Hydrochlorothiazide versus a non-diuretic dose of torasemide as once-daily anti-hypertensive monotherapy in elderly patients. A randomized and double-blind study. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 183–209.

    Google Scholar 

  62. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertensive patients with 2.5 mg torasemide/day or 50 mg triamterene/25 mg hydrochlorothiazide/day. In: Kruck F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21–23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 211–20.

    Google Scholar 

  63. Data on file, Boehringer Mannheim GmBh, Gaithersburg, MD, USA, 1994.

  64. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Ann Intern Med 1979; 91: 744–5.

    PubMed  CAS  Google Scholar 

  65. Gottl KH, Roesch A, Klinke R. Quantitative evaluation of ototoxic side effects of furosemide, piretanide, bumetanide, azosemide and ozolinone in the cat — a new approach to the problem of ototoxicity. Naunyn Schmiedebergs Arch Pharmacol 1985; 331: 275–82.

    Article  PubMed  CAS  Google Scholar 

  66. Rybak LP, Whitworth C, Scott V. Comparative acute ototoxicity of loop diuretic compounds. Eur Arch Otorhinolaryngol 1991; 246: 353–57.

    Google Scholar 

  67. Klinke R, Mertens M. Quantitative assessment of torasemide ototoxicity. Arzneimittel Forschung 1988; 38: 153–5.

    PubMed  CAS  Google Scholar 

  68. Prichard BNC, Owens CWI, Woolf AS. Adverse reactions to diuretics. Eur Heart J 1992; 13 Suppl. G: 96–103.

    PubMed  Google Scholar 

  69. Ramsay LE, Yeo WW, Jackson PR. Metabolic effects of diuretics. Cardiology 1994; 84 Suppl. 2: 48–56.

    Article  PubMed  CAS  Google Scholar 

  70. Herchuelz A, Derenne F, Deger F, et al. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance. J Pharmacol Exp Ther 1989; 248: 1175–81.

    PubMed  CAS  Google Scholar 

  71. van Ganse E, Douchamps J, Deger F, et al. Failure of indomethacin to impair the diuretic and natiuretic effects of the loop diuretic torasemide in healthy volunteers. Eur J Clin Pharmacol 1986; 31 Suppl.: 43–7.

    Article  PubMed  Google Scholar 

  72. Kramer BK, Ress KM, von Mollendorf E. Effect of the loop diuretic torasemide on serum level and renal elimination of digoxin. In: Puschett JB, Greenberg A, editors. Diuretics III: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1990: 66–8.

    Google Scholar 

  73. Kramer WG. Lack of effect of cimetidine on torasemide pharmacokinetics and pharmacodynamics in healthy subjects. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 361–4.

    Google Scholar 

  74. Piesche L, Bölke T. Comparative clinical trial investigating possible interactions of torasemide (20 mg o.d.) or furosemide (40 mg o.d.) with phenprocoumon in patients with congestive heart failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 267–70.

    Google Scholar 

  75. Kramer WG. Effect of food on the pharmacokinetics and pharmacodynamics of torsemide. Am J Ther 1995; 2: 499–503.

    Article  PubMed  Google Scholar 

  76. Moser M. Diuretics and cardiovascular risk factors. Eur Heart J 1992; 13 Suppl. G: 72–80.

    PubMed  Google Scholar 

  77. Moser M. Effects of diuretics on morbidity and mortality in the treatment of hypertension. Cardiology 1994; 84 Suppl. 2: 27–35.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Indiana University Medical Center, Emerson Hall 317, 545 Barnhill Drive, Indianapolis, Indiana, 46202-5124, USA

    D. Craig Brater

Authors
  1. D. Craig Brater
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brater, D.C. Benefits and Risks of Torasemide in Congestive Heart Failure and Essential Hypertension. Drug-Safety 14, 104–120 (1996). https://doi.org/10.2165/00002018-199614020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199614020-00005

Keywords

Search

Navigation